



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

August 20, 2019

SENT VIA EMAIL

Catherine Monahan
American Oversight
1030 15th Street NW, Suite B255
Washington, District of Columbia 20005
foia@americanoversight.org

Dear Ms. Monahan:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of July 22, 2019, seeking the following information:

...American Oversight seeks records to shed light on communications between Task Force members and drug and device manufacturers.

Requested Records

American Oversight requests that your agency produce the following records within twenty business days:

All email communications (including emails, email attachments, calendar invitations, and any attachments thereto) between or among (1) Jan L. Losby, Ph.D., M.S.W., Lead, Opioid Overdose Health Systems Team, Division of Unintentional Injury Prevention, Centers for Disease Control and Prevention, and (2) any employee or representative of the following drug and device manufacturers and their subsidiaries or affiliates:

- a. Purdue, including Purdue Pharma L.P.; Purdue Pharma, Inc.; and The Purdue Frederick Company, Inc. (@purduepharma.com)
- b. Allergan, including Allergan PLC; Allergan Finance, LLC; Allergan USA, Inc.; and Allergan Sales, LLC (@allergan.com)
- c. Teva, including Teva Pharmaceuticals Industries, Ltd.; Teva Pharmaceuticals USA, Inc.; Cephalon, Inc.; Watson Laboratories, Inc.; Warner Chilcott Company, LLC; Actavis Pharma, Inc.; Actavis South Atlantic LLC; Actavis Elizabeth LLC; Actavis Mid Atlantic LLC, Actavis Totowa LLC; Actavis LLC; Actavis Kadian LLC; Actavis Laboratories UT, Inc.; Actavis Laboratories FL, Inc.; and Andrx Corporation (@tevapharm.com)
- d. Johnson & Johnson, including Janssen Pharmaceuticals, Inc.; Ortho- McNeil-Janssen Pharmaceuticals, Inc.; and Janssen Pharmaceutica, Inc. (@its.jnj.com; @jnj.com)

- e. Endo, including Endo Health Solutions Inc., Endo Pharmaceuticals, Inc.; Endo International plc; Par Pharmaceutical, Inc.; and Par Pharmaceuticals Companies, Inc. (@endo.com)
- f. Mallinckrodt, including Mallinckrodt plc; Mallinckrodt LLC; and SpecGx LLC (@mnk.com)
- g. Insys Therapeutics, Inc. (@insysrx.com)
- h. Noramco, Inc. (@noramco.com)
- i. Assertio Therapeutics, Inc. (f/k/a Depomed, Inc.) (@assertiotx.com; @depomed.com)
- j. Eli Lilly and Company (@lilly.com)
- k. Pfizer, including Pfizer Inc. and King Pharmaceuticals LLC (@pfizer.com)
- l. Iroko Pharmaceuticals, including Iroko Pharmaceuticals, LLC and Iroko Pharmaceuticals, Inc. (@iroko.com)
- m. Daiichi Sankyo, including Daiichi Sankyo, Inc. and American Regent (@dsi.com)
- n. Stimwave, including Stimwave Technologies, Inc. and Stimwave LLC (@stimwave.com)
- o. Braeburn Inc. (@braeburnrx.com)
- p. Medtronic plc (@medtronic.com)

This request includes all prior messages (whether incoming or outgoing) reflected in the responsive correspondence and any attachments thereto.

To the extent that an email address or domain is listed in parentheses for a drug or device manufacturer, American Oversight requests that your agency search for email communications from anyone at that organization including but not limited to any person using the parenthetical email address or domain.


Please provide all responsive records since May 1, 2018, through the date of the search (See attached.).

A search of our records failed to reveal any documents pertaining to your request. Specifically, CDC conducted an enterprise search of the email system for Jan Losby and any employee or representative of the drug and device manufacturers and their subsidiaries or affiliates listed above in items a-p within the prescribed time frame and found no records.

You may contact our FOIA Public Liaison at 770-488-6277 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. Please mark both your appeal letter and envelope “FOIA Appeal.” Your appeal must be postmarked or electronically transmitted by Monday, November 18, 2019.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized, cursive script.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
Phone: (770) 488-6399
Fax: (404) 235-1852

#19-00994-FOIA